Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants 55 to 90 years of age, inclusive, at the time of informed consent.~* Participants who are residing at their current location for at least 14 days before screening and are expected to remain at the same location for the duration of the trial.~* Participants with a diagnosis of probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association.~* Participants with a Mini-Mental State Exam score of 5 to 22, inclusive, at screening and baseline visits.~* Participants with onset of symptoms of agitation at least 2 weeks prior to the screening visit.~* Participants with a score of ≥ 4 on the agitation/aggression item of the Neuropsychiatric Inventory-Nursing Home at the screening and baseline visits.~* Participants who require pharmacotherapy for treatment of agitation per the investigator's judgment, after an evaluation for reversible factors (for example, pain, infection, polypharmacy) and a trial of nonpharmacological intervention.~* Participants must have a previous magnetic resonance imaging or computed tomography of the brain, which was performed after the onset of symptoms of dementia, with findings consistent with the diagnosis of Alzheimer's disease.~Exclusion Criteria:~* Participants with dementia or other memory impairment not due to Alzheimer's disease~* Participants with a history of stroke, well-documented transient ischemic attack, pulmonary or cerebral embolism.~* Participants who currently have clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.~* Participants who have been diagnosed with an Axis I disorder (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision criteria)~* Participants with uncontrolled hypertension~* Participants with uncontrolled insulin-dependent diabetes mellitus~* Participants with epilepsy or a history of seizures~* Participants considered in poor general health based on the investigator's judgment.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo once daily
- Brexpiprazole 1 mg (Type: EXPERIMENTAL): Titrate up from 0.25 milligrams (mg)/day brexpiprazole to 1 mg/day brexpiprazole
- Brexpiprazole 2 mg (Type: EXPERIMENTAL): Titrate up from 0.25 mg/day brexpiprazole to 2 mg/day brexpiprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).